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Abstract: Rituximab is an important and well established component in the treatment of
many patients with B-cell non-Hodgkin lymphoma. In this paper we review recent clinical trials investigating the addition of rituximab to standard chemotherapy regimens for treatment of
patients with diffuse large B cell lymphoma and follicular lymphoma. This report focuses upon
treatment efficacy, quality of life, and safety of rituximab or rituximab-containing regimens.
More uniquely, we review economic aspects of lymphoma treatments, including the cost of
standard chemotherapy regimens with or without rituximab, cost effectiveness of rituximab in
both induction and maintenance treatment, and lymphoma’s impacts on patient’s productivity
and their caregivers. We conclude that adding rituximab to standard chemotherapy treatment
for patients with B-cell non-Hodgkin lymphoma is safe and cost-effective in numerous settings
during both induction and maintenance therapies. Despite extensive review of the literature,
many important questions have yet to be answered in the rituximab era and these represent
important directions for future study.
Keywords: rituximab, lymphoma, cost effectiveness, transplant, safety

Introduction
Rituximab, an anti-CD20 monoclonal chimeric antibody, has significantly improved
the prognosis of patients with B-cell non-Hodgkin lymphoma (NHL) and changed the
economics of care delivery for these patients. Diffuse large B-cell lymphoma (DLBCL)
is the most common histologic subtype of B-cell NHL accounting for approximately
25% of NHL cases.1,2 In 2005 the incidence rate of DLBCL in the United States
was approximately 5 cases per 100,000 persons. Incidence varies by ethnicity with
Caucasian Americans having the highest rates. Incidence increases with age; the median
age at presentation is 64 years, and like most NHL there is a male predominance (male:
female ratio 1.2:1).3 Follicular lymphoma (FL) is the second most common lymphoma
in the western world accounting for more than 70% of indolent lymphomas and 22%
of all NHL.3 It has 3 grades, grade I and II are indolent lymphomas while grade III
is considered by many experts to be an aggressive lymphoma. It typically occurs in
middle-aged or elderly adults with the median age at presentation of 60 years and a
slight female predominance (male to female ratio 1:1.4).3
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Rituximab
Rituximab was the first widely adopted monoclonal antibody approved for cancer
treatment. Rituximab is a monoclonal antibody directed against the CD20 antigen on
B-lymphocytes. CD20 functions as a calcium channel important in B-cell survival.
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Rituximab’s mechanism of action results from a combination
of immune-mediated effects and possibly direct induction of
apoptosis from binding to CD20. When rituximab binds to
CD20 at the cell surface rituximab activates complementdependent cytotoxicity and human Fc receptors, mediating
cell killing through an antibody-dependent cellular toxicity.
As has been previously reviewed, the predominant mechanism of rituximab’s anti-lymphoma activity is thought to
be antibody-dependent cell-mediated cytotoxicity, with a
lesser role for complement fixation.4 Although rituximab
has multiple clinical uses, including autoimmune and rheumatologic disorders, this review focuses upon rituximab’s
use in B-cell NHL.

DLBCL treatment
The addition of rituximab concurrently with cytotoxic chemotherapy has improved the cure rates for patients with DLBCL
(Table 1). Prior to the introduction of rituximab, SWOG-8516
(South Western Oncology Group) a randomized phase III
trial of CHOP (cyclophosphamide, doxorubicin, vincristine,
prednisone) vs m-BACOD (low-dose methotrexate with leucovorin rescue, bleomycin, doxorubicin, cyclophosphamide,
vincristine, and dexamethasone) vs proMACE-CytaBOM
(prednisone, doxorubicin, cyclophosphamide, and etoposide,
followed by cytarabine, bleomycin, vincristine, and methotrexate with leucovorin rescue) vs MACOP-B (methotrexate
with leucovorin rescue, doxorubicin, cyclophosphamide,
vincristine, prednisone, and bleomycin) established that
CHOP remained the standard chemotherapy for patients with
advanced stage NHL demonstrating intermediate or higher
grade histologic features.5 Although other regimens induced
greater toxicities, no regimen showed an improvement in time
to treatment failure or overall survival compared to the standard CHOP.5 The addition of rituximab to CHOP resulted in

an approximately 10% absolute increase in survival beginning
at one year from initiation of therapy in patients of all ages
with minimal clinically relevant increases in toxicity.6,7 In the
MabThera International Trial (MInT), 824 patients younger
than 60 years with DLBCL (28% stage III/IV and 48%
with bulky disease) were randomly assigned to treatment
with 6 cycles of CHOP-like chemotherapy with or without
rituximab.8 Bulky and extra-nodal sites received additional
radiotherapy. After a median follow-up of 34 months, patients
assigned to Rituximab-CHOP (R-CHOP) had significantly
higher rates of 3-year event-free (79% vs 59%; P  0.001) and
overall (93% vs 84%; P  0.0001) survival. In 3 randomized
prospective studies consisting of approximately 2000 older
patients (65 years of age) with advanced DLBCL, therapy
with R-CHOP resulted in significantly higher overall survival
at 3 (approximately 70% vs 57% for CHOP alone), 5 (58% vs
45%), and 7 years.9–13
Following these reports that the addition of rituximab
to CHOP improved response rates and overall survival,
further studies were conducted to investigate the impact of
maintenance rituximab after initial chemotherapy. Patients
who received CHOP chemotherapy for induction treatment
have an initially improved survival when administered
maintenance rituximab following CHOP chemotherapy compared to patients who received CHOP chemotherapy only.11
However, survival benefit disappeared with longer follow-up
suggesting that unlike induction combination chemotherapy
with rituximab, rituximab maintenance may delay clinically
evident progression but does not increase the cure rate.14
Additionally, maintenance therapy with rituximab provided
no significant benefit in those who received initial therapy
with R-CHOP for DLBCL.14
Although the addition of rituximab to CHOP has
improved the cure rates for patients with DLBCL,

Table 1 Treatment of diffuse large B-cell lymphoma
Trial

Treatment

Follow-up
period

Results

Schema

P value

MInT8
N = 824

CHOP
R-CHOP

34 months

EFS: 59% OS: 79%
EFS: 84% OS: 93%

1st line

EFS P  0.001
OS P  0.0001

Habermann11
N = 415

CHOP
R-CHOP

3 years

FFS: 46%
FFS: 53%

1st line

P = 0.04

Coiffier13
N = 399

CHOP
R-CHOP

7 years

EFS: 25% OS: 36%
EFS: 42% OS: 53%

1st line

EFS P  0.0001
OS P = 0.0004

Kewalramani15
N = 36

ICE
R-ICE

2 years

CRR: 27% PFS: 43%
CRR: 53% PFS: 54%

2nd line

PFS P = 0.25
CRR P = 0.01

Abbreviations: EFS, event-free survival; OS, overall survival; FFS, failure-free survival; CRR, complete response rate; PFS, progression-free survival.
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a significant portion of patients still have recurrence and
require additional therapies. Rituximab may play an important role in addition to standard chemotherapies in this
setting as well. Thirty-six patients with relapsed or refractory DLBCL were treated with rituximab plus ifosfamide,
carboplatin, and etoposide (R-ICE).15 The complete response
rate was 53%, significantly better than the historical control
rate of 27% achieved for DLBCL treated with ICE alone
(P = 0.01). Progression-free survival rates of patients who
underwent transplantation after R-ICE trended toward
improvement compared to historical controls who underwent
transplantation after ICE (54% vs 43% at 2 years) but weren’t
statistically significant in this analysis (P = 0.25). The ICE
and R-ICE regimens have been very effective cytoreduction
and stem cell mobilization regimens, and reasonable options
for patients eligible for subsequent hematopoietic stem cell
transplant (HSCT).15,16
Hematopoietic stem cell transplantation (HSCT) is a clinically necessary treatment for many patients with DLBCL and
significantly impacts the economics of these patients’ care. In
the United States, autologous HSCT is considered standardof-care for many patients who achieve a second remission
from DLBCL following a first recurrence. HSCT during the
first remission is associated with significant morbidity and
survival is similar in patients administered chemotherapy
with or without HSCT.17 An intergroup trial (S9704) enrolled
patients with high intermediate and high risk international
prognostic index (IPI) scores according to age-adjusted index
and randomized treatment to 6 cycles of R-CHOP followed
by autologous HSCT vs 8 cycles of R-CHOP alone. We await
results of this United States intergroup trial before recommending HSCT for this subgroup of patients.
Including rituximab with HSCT may improve the
clinical results achieved with HSCT chemotherapy alone.
A Phase III randomized trial (CORAL) comparing two
rituximab-based regimens both followed by HSCT and
maintenance rituximab or not in relapsed or refractory
DLBCL found that rates of 2-year event-free survival were
significantly reduced in a subset of patients with prior exposure to rituximab when compared with patients who were
rituximab-naïve.18,19 In one modest-sized study, rituximab
was given to 35 patients with recurrent or refractory aggressive NHL (25 with DLBCL) following high-dose therapy
and autologous HSCT.20 Rituximab was given for 4 weeks
starting at day 42 post-HSCT in all patients, and again at 6
months post-HSCT in 31 patients. At a median follow-up of
30 months, the estimated 2-year event-free and overall survivals were 81% and 85%, respectively, for the 21 patients
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with relapsed or refractory DLBCL. Although delayed and
severe neutropenia, including some patients with an absolute
neutrophil count less than 500/mm3, as well as profound
B-cell inhibition were observed, the treatment program
was well-tolerated. In a second trial, high-dose rituximab,
1000 mg/m2 rather than standard-dose 375 mg/m2, was
administered during stem cell mobilization, BEAM (carmustine, etoposide, cytarabine, melphalan) chemotherapy,
and on days 1 and 8 after HSCT in 67 patients.21 At a median
follow-up of 20 months, estimated 2-year disease-free and
overall survival (OS) were 67% and 80%, respectively
(P = 0.002), significantly better than those of a historical
control group receiving the same preparative regimen without rituximab 43% and 53%, respectively (P = 0.004).

FL treatment
Unlike DLBCL, no consensus exists for a standard-of-care
initial treatment for patients with newly diagnosed FL.
Indeed, the decision to begin treatment as opposed to continued observation is often a subjective decision. In the
United States, significant regional variations exist in the
care of patients with FL. For example, initial observation
without treatment was recommended for 29% of patients in
the northeast but only 13.3% of patients in the southeast.22
Cyclophosphamide, doxorubicin, and fludarabine based
regimens may all be considered for first and subsequent
treatments (Table 2).
The most commonly prescribed initial treatment for FL
is R-CHOP, the same regimen that is considered standard-ofcare for DLBCL.22 The initial trial of R-CHOP for patients
with de novo and recurrent FL reported a 95% response
rate and 55% complete response rate.23 Subsequently,
a randomized trial of CHOP vs R-CHOP for initial treatment
of patients with FL reported a 90% response rate and 17%
complete response rate for CHOP vs 96% and 20% respectively for R-CHOP (P = 0.011).24 For patients who do not
receive CHOP for initial therapy, CHOP is often considered
for second line therapy. As a second-line treatment, R-CHOP
therapy has a significantly higher complete response rate
than CHOP therapy alone, 30% vs 16% (P  0.0001), which
translated into a significantly prolonged median progression-free survival (PFS) from first randomization, 33.1 vs
20.2 months (P = 0.0003).25
Another common FL treatment regimen, cyclophosphamide, vincristine, and prednisone (CVP) is significantly
improved with the addition of rituximab.26 Adding rituximab
to CVP (R-CVP) in previously untreated patients with
stage III/IV FL improves complete response rates from
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Table 2 Treatment of follicular lymphoma
Trial

Treatment

Results

Schema

P value

Hiddemann24
N = 428

CHOP
R-CHOP

RR: 90% CR: 17%
RR: 96% CR: 20%

1st line

P = 0.011

van Oers25
N = 465

CHOP
R-CHOP

ORR: 72% CR: 16%
ORR: 85% CR: 30%

2nd line

P  0.001

RM
OBS

PFS: 52 mo OS: 85%
PFS: 15 mo OS: 77%

2nd line

PFS P  0.001
OS P = 0.011

Marcus26
N = 321

CVP
RCVP

CRR: 57% OS: 77%
CRR: 81% OS: 83%

1st line

CRR P  0.0001
OS P = 0.029

Forstpointner27
N = 65

FCM
R-FCM

ORR: 70% CR: 23%
ORR: 94% CR: 40%

1st line

ORR P = 0.011

Rummel28
N = 437a

R-CHOP
BR

ORR: 93% CR: 33%
ORR: 94% CR: 41%

1st line

Not reported

Robinson29
N = 67b

BR

ORR: 92% CR: 41%

2nd line

CI 95%

52% of the patients had follicular lymphoma, 20% had mantle cell lymphoma and 28% had other lymphoma.
patients had indolent non-Hodgkin lymphoma and mantle cell lymphoma.
Abbreviations: CI, confidence interval; RM, rituximab maintenance; OBS, observation; BR, bendamustine with rituximab; mo, month; RR, response rate; CR, complete response;
ORR, overall response rate; PFS, progression-free survival; OS, overall survival.
a

b

57% to 81% and improves overall survival after 53 months
median follow up from 77% to 83% without increasing serious adverse events (P  0.0001).
Regimens containing fludarabine, a nucleoside analogue,
have shown high response rates and are another considerable regimen for initial and subsequent therapy for patients
with FL. Patients receiving R-FCM (rituximab, fludarabine,
cyclophosphamide, mitoxantrone) as induction therapy will
achieve significantly higher complete response (CR) and
overall response rates (ORR) than those who receive induction with FCM alone.27 In a trial that combined patients
with relapsed FL and mantle cell lymphoma and randomized patients to receive FCM with or without rituximab, the
R-FCM arm was significantly superior in ORR, PFS and OS.
In the FL subgroup, the patients receiving the rituximabcontaining induction arm had a 94% ORR vs 70% in FCM
alone arm (P = 0.011); PFS was also significantly longer in
the R-FCM arm (P = 0.0139).
More recently, bendamustine and rituximab (BR) combinations have been studied in patients requiring initial
treatment of FL and in patients with relapsed disease. In
the frontline setting, BR has a similar overall and complete
response rate 94% and 41% compared to R-CHOP 93% and
33%.28 The R-CHOP arm also had more hematologic and
infectious toxicities than the BR arm.28 For patients with
relapsed FL, BR has reported a 92% response rate with 41%
complete response in a study of 67 patients.29 Increasingly,
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BR is reasonable treatment option for initial or subsequent
treatment for patients with FL.
Radioimmunotherapy, linkage of monoclonal antibody to
radioisotope for intravenous administration, is another treatment option for patients with FL. In patients with advanced
stage FL receiving I131-tositumomab as initial therapy, 95%
responded and 75% had a complete response.30 Radioimmunotherapy has also been investigated as a consolidation
therapy after cytotoxic chemotherapy. An international, randomized, phase III trial evaluated the efficacy and safety of
consolidation with Yttrium90 ibritumomab tiuxetan in patients
with advanced-stage FL in first remission. Consolidation
with Y90-ibritumomab tiuxetan is highly effective with no
unexpected toxicities, prolonging PFS by 2 years and resulting in high partial response (PR) conversion to CR rates with
multiple first-line induction combinations.31
Maintenance treatments with rituximab after patients
are in remission from FL are effective at delaying time
until recurrence in some instances for patients with FL.
Two phase II trials of rituximab maintenance after rituximab monotherapy induction suggested that rituximab as a
first-line treatment with scheduled maintenance at 6-month
intervals produces high overall and complete response
rates and a longer PFS , 34 months, than has been reported
with a typical 4-week treatment alone.32,33 The Phase III
Swiss Group for Clinical Cancer Research (SAKK) 35/98
trial enrolled both newly diagnosed and previously treated
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patients with FL. Overall, 151 patients (51 of whom were
previously untreated) achieved CR, PR, or stable disease
after rituximab monotherapy induction (four once weekly
doses) and were subsequently randomized to either no further treatment or rituximab maintenance therapy consisting
of four single rituximab infusions administered at 2-month
intervals. In the initial publication, with a median follow-up
of 35 months, median event-free survival among all patients
receiving maintenance therapy was significantly longer than
that achieved by patients receiving no further treatment, 23 vs
12 months (P = 0.024).34 With 8 years of follow-up, no longterm toxicities were attributable to maintenance rituximab
and 20% of patients still remained in remission.35 Overall
this study showed that rituximab maintenance after rituximab
monotherapy induction significantly improves outcomes in
FL in terms of both response duration and event free survival,
without causing additional toxicity. Recently, a comprehensive review and meta-analysis concluded that maintenance
therapy with rituximab, either as 4-weekly infusions every
6 months or as a single infusion every 2 to 3 months, should
be added to standard therapy for patients with relapsed or
refractory FL after successful induction therapy.36
Rituximab maintenance after initial chemotherapy induction is significantly better than induction chemotherapy alone.
A Phase III trial conducted by the Eastern Co-operative
Oncology Group (ECOG 1496) studied 305 evaluable
patients with newly diagnosed advanced stage indolent
NHL.37 Most of these patients, 78%, had advanced stage FL.
Those patients achieving a complete or partial response
or stable disease following CVP induction chemotherapy
were randomized to either rituximab maintenance therapy
or standard observation. The rituximab maintenance was
dosed weekly for 4 doses and repeated at 6-month intervals
for up to 2 years. Analyses conducted in the FL subgroup
revealed 3-year PFS after random assignment was 64% for
the maintenance group vs 33% for the observation group
(hazard ratio [HR] = 0.4; P  0.001). Among patients with
FL, OS at 3 years was 91% for the maintenance group vs 86%
for the observation group (HR = 0.6; P = 0.08). This study
provides strong evidence that rituximab maintenance has a
significant survival benefit for patients with FL who receive
induction chemotherapy without the inclusion of rituximab
during induction.
Similar, but more compelling, conclusions have been
drawn in the relapsed setting. In European Organization for
the Research and Treatment of Cancer (EORTC) protocol
20891, patients were randomized to CHOP or R-CHOP
induction therapy for a first recurrence of FL. After six cycles
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of induction chemotherapy; patients who achieved complete
or partial responses underwent another randomization to
rituximab maintenance or standard observation. Rituximab maintenance significantly prolonged the PFS from
14.9 months in the observation to 51.5 months (P  0.0001);
rituximab maintenance also improved OS at 3 years from
77% with observation alone to 85%.25 In a subgroup analysis
of patients who received CHOP for induction, rituximab
maintenance resulted in a median PFS from second randomization of 42.2 months vs 11.6 months in the observation
arm (HR, 0.30; P  0.001). For patients receiving R-CHOP
induction, rituximab maintenance resulted in a median PFS
from second randomization 51.8 months vs 23.0 months in
the observation arm (HR, 0.54; P = 0.004). As a conclusion
from this study; rituximab maintenance was still beneficial
after R-CHOP induction but a survival benefit was clearer
in patients who only received CHOP induction.
Maintenance rituximab after autologous HSCT is another
interesting treatment consideration. The efficacy and safety
of rituximab maintenance therapy administered once monthly
after autologous HSCT were retrospectively analyzed in
27 patients with NHL treated at a single institution.38 Of these
27 patients, 12 had FL and were in CR at the time of transplantation. After a median follow-up period of 30 months,
all 12 patients were still alive and, except for 1 patient who
transformed from indolent to aggressive disease, there were
no relapses. Another study incorporated in vivo purging
with rituximab around the time of stem cell pheresis with
maintenance rituximab after autologous HSCT. Twenty-three
patients with relapsed FL were enrolled in this prospective
single-arm study.39 Five-year OS and 5-year PFS are 78%
(95% confidence interval [CI] 61% to 95%) and 59% (95%
CI 38% to 80%), respectively. Time to progression with the
rituximab-containing regimen was significantly improved
compared with each patient’s previous treatment (P  0.001).
Durable molecular remissions, documented by quantitative polymerase chain reaction testing, occurred in 11 of
13 patients. Despite the prolonged hypogammaglobulinemia,
no increase in major infections was observed.

Cost of lymphomas
The loss of life-years from DLBCL is hard to estimate and
we found no previous reports in our review of the literature.
A retrospective analysis of 374 patients with newly diagnosed stage II–IV aggressive NHL treated between 1993
and 2001 in The Netherlands with CHOP chemotherapy
showed the mean first-line treatment costs (excluding G-CSF)
were €10,047 ($10,254) for patients younger than 60 years
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of age and €12,232 ($12,484) for patients older than 60.40
Two-year follow-up costs averaged €14,039 ($14,328) and
€9,026 ($9,211) for the two age groups, respectively. A large
retrospective analysis of direct medical costs for the entire
pathway of care for DLBCL was conducted between 1998
and 2004 in Canada.41 Patient samples were defined as those
who received R-CHOP (n = 85) or CHOP (n = 86) as first-line
treatment. CHOP cost was CAN$12,240 ($8,800) and the
1-year follow up cost was CAN$8,929 ($6,400) compared to
R-CHOP cost of CAN$33,088 ($22,680) with 1-year follow
up costs of CAN$3,215 ($2,311). In European healthcare
systems between 2000 and 2003, the mean cumulative cost
of CHOP was $3,358 and R-CHOP was $17,225.42 The posttreatment cancer surveillance cost for CHOP was $3,950
compared with $5,202 for R-CHOP.
Often thought of as one of the most costly treatments,
HSCT adds significant expense to the care of patients who
require this modality of care. For patients with refractory or
relapsed NHL, the cost from induction chemotherapy until
3 months after discharge from inpatient care following the
transplant was €15,000 ($15,300) from 1994 to 1998 in
The Netherlands.43 Similarly, the cost for autologous HSCT
for the Canadian system in 1993/1994 was CAN$ 22,089
($16,029).44
The loss of life-years is harder to estimate from FL
because patients may undergo multiple series of treatments
over a decade or more after diagnoses. Although the attempts
to capture the costs of chemotherapy for FL have not always
accounted for infusion related and follow up costs, in 2007
the cost of 8 cycles of CVP in the US was $500, 6 cycles
R-CVP $24,500, and CHOP as salvage over 6 months costs
$3,829.45 Further, autologous HSCT for treatment of FL in
the US in 2007 was estimated to cost $75,352.45 Although
this cost is much higher than reviewed for DLBCL, this difference is likely related to healthcare inflation and differences
in cost between healthcare systems and not due to differences
between the diseases. As with DLBCL, the cost to patients
and families for lost productivity is likely significant, but has
not been well measured.
Despite the extensive publications about NHL treatments,
little is known about how treatment impacts on patients’ work
and daily activities. A cross-sectional study of work productivity, activity impairment, and impacts on caregivers was
conducted with 84 patients with NHL. Of the 71% of patients
who worked before diagnosis; only 41% continue to work
after treatment with 36% transitioning to retirement, sick
leave (10%) and unemployment (4%).46 Active chemotherapy
treatment was associated with significant activity impairment
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(OR 14.5; 95% CI 0.91 to 230.9; P = 0.059). A significant
proportion of patients required caregiver assistance (23%);
with 33% of their working days being missed as a consequence of this care.46 Those caregivers suffered from physical,
psychological, and financial disruptions. Another large cohort
study reported that 13% of all survivors had stopped working
for cancer-related reasons within 4 years of diagnosis. More
than 50% of all survivors had stopped working after the first
year with 75% of those who stopped working returning to
work in the future when they are off treatment.47 Survivors
of stage IV blood and lymph malignancies have one of the
highest adjusted risk of disability or quitting work amongst
all patients with cancer.47
Given the high costs of these illnesses and their treatments; much work has gone into determining the most
cost-effective approaches for care delivery (Table 3).
A cost-effectiveness analysis of CHOP vs R-CHOP for initial treatment of patients with DLBCL has been presented
from a European payer perspective.48 Chemotherapy cost
was estimated from a phase III trial in France, Belgium,
and Switzerland. The survival and cost-effectiveness was
estimated from 4 years to 15 years. R-CHOP resulted in
20.6% relative increase in complete response rate, absolute
increase from 63% to 76%, and a 31% decrease in risk of
death at four years. Over 15 years mean, median OS was
estimated to be 6.9 years for R-CHOP and 5.74 years for
CHOP, a mean increase in OS of 1.16 years (or 1.07 quality adjusted life year [QALY]s). Total direct medical costs
were €13,170 ($11,250) higher with R-CHOP, with an
incremental cost-effectiveness ratio of €12,259 ($10,477) per
QALY gained which looks favorable comparing to standard
worldwide accepted ranges. Similarly, the incremental cost
effectiveness of CHOP vs R-CHOP in DLBCL patients in
Netherlands has been reported.49 A transition state model was
developed to estimate the clinical course, costs and quality

Table 3 Cost of diffuse large B-cell lymphoma treatment
Study

Treatment

Follow-up
period

Cost
1st line
cost

Follow-up
cost

5 years

$3,358
$17,225

$3,950
$5,202

van Agthoven43 CHOP
N = 374

2 years

$10,254–
$12,232

$9,211–
$14,328

Lee41
N = 171

1 year

$8,800
$22,680

$6,400
$2,311

Hornberger42
N = 399

CHOP
R-CHOP

CHOP
R-CHOP
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of life (QOL) differences between the two groups. The only
costs included were direct medical costs. The time horizon
of the model was 15 years. The incremental gain was 0.88
QALYs favoring the addition of rituximab to CHOP. The
costs were €12,343 ($10,550) higher in the younger group of
patients and €15,860 ($13,555) in the older patients.49 This
resulted in an incremental cost-effectiveness ratio (ICER) of
€13,983 ($11,950) for the younger and €17,933 ($15,327) for
the older patients per QALY gained.49 An additional study
compared the direct medical cost of CHOP and R-CHOP in
young patients with favorable IPI risk DLBCL from the perspective of the Italian National Health Service.50 The model
provided an estimate of mean survival and mean costs over a
3-year period. The QALYs gained with R-CHOP was greater
than with CHOP. In the R-CHOP regimen, the additional
costs of rituximab €10,086 ($14,780) were balanced by the
lower additional therapy costs €10,803 ($15830) leading to a
lower overall mean treatment cost per patient with R-CHOP
regimen than with the CHOP regimen €22,113 ($32,400) vs
€22,831 ($33,460).
In FL, the cost effectiveness of adding rituximab to CVP
has been reported45 and the mean overall survival is projected
to be 1.51 years longer for patients receiving R-CVP than
CVP. The cost per QALY gained is $28,565 and the ICER
of R-CVP compared with CVP is projected to be acceptable under a range of sensitivity analyses in the United
States. The cost-effectiveness of maintenance rituximab
for US patients with FL in second remission has also been
reported.51 Five years after R-CHOP and achieving a second
remission, disease-free survival is expected to be 47% and
22%, and the OS rates are estimated to be 73% and 61% for
extended adjuvant rituximab and observation, respectively.
The discounted ICER for the addition of adjuvant rituximab
is estimated to be $19,522 per QALYs gained. The authors
concluded that maintenance rituximab offers a clinical benefit
to patients who have a second remission from FL at a cost
generally acceptable to the US healthcare system. Similarly,
a cost-effectiveness analysis of maintenance rituximab during
second remission for patients in Sweden was conducted and
concluded to be a reasonable value for patients who achieve
a complete response to induction chemotherapy.52

Patient focused outcomes
The addition of rituximab to CHOP chemotherapy may not
add significantly to the symptoms or toxicities of CHOP
chemotherapy alone. QOL was evaluated during a prospective randomized trial of rituximab maintenance therapy
in 91 NHL patients (38 with DLBCL and 16 with FL).53
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QOL was assessed with the standardized questionnaires
EORTC-QLQ-C30, EuroQol-5D, and EuroQol-5D (VAS).
No differences in QOL were found between the groups
that received rituximab maintenance or standard observation. We are not aware of any reports that have specifically
ascertained patient satisfaction with receiving rituximab
during treatment for DLBCL or adherence with treatment
recommendations. Similarly, uptake of R-CHOP in place of
CHOP seems nearly universal when health care systems are
able to offer rituximab, although objective data to support
this belief are lacking.
In FL, the addition of rituximab to CHOP did not clinically significantly increase the toxicity of induction therapy.25
In SAKK 35/98, maintenance rituximab was well tolerated. Of
the 137 patients who were evaluable for toxicity, only 7% in both
the maintenance and observation arms reported toxicities.34 In
Eastern Cooperative Oncology Group (ECOG) protocol 1496,
rituximab maintenance or observation after induction therapy
with CVP, rituximab maintenance was well tolerated and did
not lead to significantly higher rates of neutropenia, thrombocytopenia, or infection compared with observation alone.37 In
EORTC 20891, rituximab maintenance vs observation after
induction therapy with either CHOP or R-CHOP, rituximab
maintenance treatment was associated with minimal toxicity.25
Only 6 out of 167 patients (4%) had to discontinue treatment
because of toxicity. Four of the six patients were discontinued
due to infections, and there was no treatment-related mortality.
As in DLBCL, patient satisfaction, acceptability, physician
uptake, and adherence have been widely reported and our
literature review failed to return any relevant reports.

Future directions
Although there are many investigations of rituximab in NHL
many questions still await an answer. Despite the fact that
all studied maintenance schedules have been shown to be
effective in FL; we are still unsure about the optimal dosing, schedule, and duration of this maintenance. Because all
of the rituximab maintenance studies have been conducted
over the last 7 years, there is no clear guidance yet about
long term safety and efficacy. Questions remain about the
risks of decreased immunoglobulin levels and infection rates,
activating cutaneous squamous cell carcinoma, and selection
for CD20 negative lymphoma relapses. Questions about the
long-term safety require longer follow up. The impact of
rituximab maintenance on patient’s QOL and productivity and caregiver burden should be studied further. Some
researchers and advocates have suggested that receiving
maintenance treatments may reduce QOL due to treatment
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burden but others have advocated that maintenance may
increase patient’s feeling of satisfaction as they participate
in actively managing their disease. Further research is clearly
indicated. Despite our careful review, we are not aware of
data to assess patients’ acceptance or physicians’ uptake of
rituximab. Although treatment with rituximab is clinically
beneficial in several patient settings, future investigations
may allow doctors and patients to optimize the treatment
effect and refine approaches that improve patient-focused
outcomes and limit economic burden.
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